Kumar Prabhash

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta et al. · The Lancet · 2014 · 1.3K citations · Full text

Platinum-based Therapy, Disease Progression, Medicine +10

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer

Vanita Noronha, Vijay Patil, Amit Joshi et al. · Journal of Clinical Oncology · 2019 · 415 citations

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena et al. · Journal of Thoracic Oncology · 2012 · 339 citations · Full text

Medicine, Cancer Management, Clinical Trials +8

Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial

Vanita Noronha, Amit Joshi, Vijay Patil et al. · Journal of Clinical Oncology · 2017 · 326 citations

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial

Vedang Murthy, Priyamvada Maitre, Sadhana Kannan et al. · Journal of Clinical Oncology · 2021 · 308 citations